| Paul G Degregorio, MD | |
|
2 Pillsbury St Ste 100, Concord, NH 03301-3549 | |
| (603) 224-2020 | |
| (603) 228-7061 |
| Full Name | Paul G Degregorio |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 32 Years |
| Location | 2 Pillsbury St Ste 100, Concord, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508850827 | NPI | - | NPPES |
| 0109320Y0NH01 | Other | NH | ANTHEM NH |
| 180035688 | Other | NH | RAILROAD MEDICARE |
| 30200390 | Medicaid | NH | |
| 5805901003 | Other | NH | CIGNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 10500 (New Hampshire) | Secondary |
| 207WX0107X | Ophthalmology - Retina Specialist | 10500 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Concord Hospital | Concord, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Concord Ophthalmologic Associates Pa | 0547250920 | 15 |
News Archive
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.
Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Chris Rusconi, PhD, Senior Vice President, Chief Scientific Officer and Steven Zelenkofske, DO, FACC, Senior Vice President , Chief Medical Officer presented an abstract at the American College of Cardiology on Monday, March 15, 2010 in Atlanta, Georgia.
Aging with Dignity President Paul Malley praised President Barack Obama's Executive Order dated April 15, 2010 in which he instructs hospitals participating in Medicare/Medicaid to allow bedside access to the patient's legally designated health care agent.
People on welfare can earn more money in their jobs - and potentially leave the program - if the trauma they've faced since childhood is addressed, Drexel University research shows.
The partners in a new publicly-funded European research project today announced details of the multinational/multidisciplinary program: 'CSI: Central Nervous System Imaging.' This three-year ENIAC project aims to achieve substantial advances in state-of-the-art medical 3D-imaging platforms by focusing on the diagnosis and therapy of serious diseases of the central nervous system and brain.
› Verified 1 days ago
| Entity Name | Concord Ophthalmologic Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831183268 PECOS PAC ID: 0547250920 Enrollment ID: O20040517001006 |
News Archive
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.
Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Chris Rusconi, PhD, Senior Vice President, Chief Scientific Officer and Steven Zelenkofske, DO, FACC, Senior Vice President , Chief Medical Officer presented an abstract at the American College of Cardiology on Monday, March 15, 2010 in Atlanta, Georgia.
Aging with Dignity President Paul Malley praised President Barack Obama's Executive Order dated April 15, 2010 in which he instructs hospitals participating in Medicare/Medicaid to allow bedside access to the patient's legally designated health care agent.
People on welfare can earn more money in their jobs - and potentially leave the program - if the trauma they've faced since childhood is addressed, Drexel University research shows.
The partners in a new publicly-funded European research project today announced details of the multinational/multidisciplinary program: 'CSI: Central Nervous System Imaging.' This three-year ENIAC project aims to achieve substantial advances in state-of-the-art medical 3D-imaging platforms by focusing on the diagnosis and therapy of serious diseases of the central nervous system and brain.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul G Degregorio, MD 2 Pillsbury St Ste 100, Concord, NH 03301-3502 Ph: (603) 228-1104 | Paul G Degregorio, MD 2 Pillsbury St Ste 100, Concord, NH 03301-3549 Ph: (603) 224-2020 |
News Archive
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.
Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Chris Rusconi, PhD, Senior Vice President, Chief Scientific Officer and Steven Zelenkofske, DO, FACC, Senior Vice President , Chief Medical Officer presented an abstract at the American College of Cardiology on Monday, March 15, 2010 in Atlanta, Georgia.
Aging with Dignity President Paul Malley praised President Barack Obama's Executive Order dated April 15, 2010 in which he instructs hospitals participating in Medicare/Medicaid to allow bedside access to the patient's legally designated health care agent.
People on welfare can earn more money in their jobs - and potentially leave the program - if the trauma they've faced since childhood is addressed, Drexel University research shows.
The partners in a new publicly-funded European research project today announced details of the multinational/multidisciplinary program: 'CSI: Central Nervous System Imaging.' This three-year ENIAC project aims to achieve substantial advances in state-of-the-art medical 3D-imaging platforms by focusing on the diagnosis and therapy of serious diseases of the central nervous system and brain.
› Verified 1 days ago
Maynard B Wheeler, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 248 Pleasant Street, Suite 1600, Concord, NH 03301 Phone: 603-224-2020 Fax: 603-228-0248 | |
Maxwell Arrington Snead Iii, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2 Pillsbury St Ste 100, Concord, NH 03301 Phone: 603-228-1104 | |
Dr. Tighe Curtis Richardson, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2 Pillsbury St Ste 100, Concord, NH 03301 Phone: 603-224-2020 Fax: 603-228-7061 | |
Andre A D'hemecourt, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2 Pillsbury St Ste 100, Concord, NH 03301 Phone: 603-228-1104 Fax: 603-228-7061 | |
Christie L Morse, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 248 Pleasant St, Suite 1600, Concord, NH 03301 Phone: 603-224-2020 Fax: 603-228-0248 | |
David Alan Weinberg, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 248 Pleasant St Ste 1600, Concord Eye Care, Concord, NH 03301 Phone: 603-224-2020 Fax: 603-228-0248 | |
Bradford S Hall, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 248 Pleasant St, Ste 1600, Concord, NH 03301 Phone: 603-224-2020 Fax: 603-228-0248 |